TIDMKMK
Kromek Group PLC
17 October 2022
17 October 2022
Kromek Group plc
("Kromek" or the "Group")
Kromek's digital detectors used in world's first digital
SPECT/CT scanner for higher energy imaging
Detectors provide Spectrum Dynamics Medical's digital SPECT/CT
scanner with higher sensitivity and throughput
Kromek Group plc (AIM: KMK), a leading developer of radiation
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments, is pleased to announce that one of its key
customers, Spectrum Dynamics Medical, has introduced the world's
first digital SPECT/CT scanner for higher energy imaging, using
Kromek's digital detectors.
Based on Spectrum Dynamics' digital SPECT/CT platform,
VERITON-CT 400 Series' detector technology provides the benefits of
increased sensitivity and throughput for Nuclear Medicine clinical
applications using up to 400keV high-energy isotopes.
CZT is transforming the detector technology used in medical
imaging leading to shorter scan times, lower radiation dose to the
patient, and improved image quality and quantitative accuracy.
Kromek's high-performance digital detectors, combined with
Spectrum's 360-degree, wide-bore SPECT/CT scanner and its advanced
image reconstruction algorithms, increase the energy range up to
400 keV to support the throughput demand of current and new
emerging nuclear medicine clinical applications.
The 400 Series digital detector technology sets new standards
with a 2-4 times improvement in energy range, system sensitivity,
and energy resolution. These improvements will significantly
shorten the scan times associated with current analog or
state-of-the-art digital technology.
Arnab Basu, CEO of Kromek Group, said: "We are delighted that
our CZT detectors have been integrated into Spectrum Dynamics'
VERITON-CT 400 SPECT/CT systems. This enables enhanced image
quality and breakthrough clinical capabilities in digital SPECT/CT.
Spectrum Dynamics has long been at the forefront of developing
next-generation SPECT/CT scanners to deliver better patient
outcomes, and we are pleased to be part of this significant advance
in nuclear medical imaging technology."
Gilad Yoeli, CEO of Spectrum Dynamics, added: "Clinical users
across the world provide us with feedback on the Nuclear Medicine
challenges they face. Providing the technology to address such
challenges is what drives us. The increased sensitivity, improved
energy resolution, and broader energy range of Kromek's detector
technology make it the right choice for the 400 Series and the
advanced imaging and quantitative accuracy clinical users ask
for."
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO +44 (0)1740 626 060
Spectrum Dynamics Medical
Nilda Rivera +1 (941) 441-6224
finnCap Ltd (Nominated Adviser and Broker)
Geoff Nash/Seamus Fricker/George Dollemore
- Corporate Finance
Tim Redfern/Charlotte Sutcliffe - ECM +44 (0)20 7220 0500
Gracechurch Group (Financial PR)
Harry Chathli, Claire Norbury +44 (0)20 4582 3500
About Kromek Group plc
Kromek Group plc is a leading developer of radiation detection
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments. Headquartered in County Durham, UK, Kromek
has manufacturing operations in the UK and US, delivering on the
vision of enhancing the quality of life through innovative
detection technology solutions.
The advanced imaging segment comprises the medical (including CT
and SPECT), security and industrial markets. Kromek provides its
OEM customers with detector components, based on its core cadmium
zinc telluride (CZT) platform, to enable better detection of
diseases such as cancer and Alzheimer's, contamination in
industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation
detection solutions to the global homeland defence and security
market. Kromek's compact, handheld, high-performance radiation
detectors, based on advanced scintillation technology, are
primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN
detection segment. These consist of fully automated and autonomous
systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange,
under the trading symbol 'KMK'.
Further information is available at www.kromek.com .
About Spectrum Dynamics Medical
Spectrum Dynamics Medical Group Limited and its subsidiaries
("Spectrum Dynamics") are engaged in developing, manufacturing,
selling, and servicing state-of-the-art nuclear medicine imaging
systems. Spectrum Dynamics is spearheading the transformation of
SPECT imaging systems from analog to digital detection technology,
enabling hospitals and clinicians to provide superior healthcare
services with improved image quality, efficiency, and access to
advanced clinical applications. Spectrum Dynamics launched the
world's first digital cardiac dedicated SPECT system - the
D-SPECT(R) CARDIO - in 2007. Since then, the D-SPECT has become the
system of choice for functional cardiac imaging, with hundreds of
systems sold worldwide. In 2018, Spectrum Dynamics launched its
multipurpose VERITON(R) and the VERITON-CT(R) SPECT/CT, the first
ring-based 360 CZT digital SPECT/CT scanner.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABDLFFLBLZFBB
(END) Dow Jones Newswires
October 17, 2022 06:42 ET (10:42 GMT)
Kromek (LSE:KMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kromek (LSE:KMK)
Historical Stock Chart
From Jul 2023 to Jul 2024